
Aptargroup (ATR) Stock Forecast & Price Target
Aptargroup (ATR) Analyst Ratings
Bulls say
AptarGroup has experienced substantial growth in its AMS Solutions segment, which has achieved a compound annual growth rate (CAGR) of approximately 10% and now constitutes about 11% of Pharma's revenue and 5% of total revenue for FY24. The company's Injectables business has also shown significant growth, marked by a 9% CAGR, driven by an increasing global demand for biologics and GLP-1 products. This combination of robust segment growth and a favorable market trend is expected to continue enhancing AptarGroup's profit margins and overall financial performance.
Bears say
AptarGroup faces significant risks that may impede its growth and profitability, particularly as its transition to a majority Pharma focus appears slower than anticipated, which could hinder margin expansion. Being a global entity, AptarGroup is exposed to various currency and country risks, as well as economic cycles that can adversely affect industry demand. Additionally, ongoing trade tensions, potential regulatory inspection failures, and challenges in protecting its intellectual property may further jeopardize its competitive position and overall financial performance.
This aggregate rating is based on analysts' research of Aptargroup and is not a guaranteed prediction by Public.com or investment advice.
Aptargroup (ATR) Analyst Forecast & Price Prediction
Start investing in Aptargroup (ATR)
Order type
Buy in
Order amount
Est. shares
0 shares